纪念斯隆-凯特琳癌症中心和中国胸部肿瘤研究协作组在年度研讨会期间加强国际合作

本文重点介绍了第三届MSK-CTONG年度研讨会，该研讨会汇集了医学专家、行业领袖和政府监管机构，讨论了国际临床试验，其中还重点关注了中美合作问题。陆克文等主要发言人强调了合作抗击癌症的重要性。纪念斯隆-凯特琳癌症中心（MSK）与中国胸部肿瘤研究协作组（CTONG）的合作旨在开展肺癌治疗的联合临床试验。这一合作伙伴关系于2018年确立，促进了两国之间知识、资源和疗法的共享。

MSK和CTONG之间的合作顺应中国新的监管环境下更为快速的新药审批。该合作伙伴关系利用这一监管变化来加速癌症患者新疗法的开发和审批。通过在“奥比斯项目”等倡议下开展合作，中美研究人员可以协调努力，在全球范围内加快审批速度，同时加强患者护理。此次合作加快了创新科学、精准医学和肺癌靶向治疗取得进展的速度。

首个中美多中心临床试验的启动标志着MSK-CTONG合作伙伴关系的一大重要里程碑。这项成果为围绕临床试验的进一步国际合作奠定了基础，特别是在将实验室科学转化为治疗的1期试验中。研讨会与会者包括行业合作者和监管机构，各方共同致力于为癌症药物研发制定协调和透明的框架。最终目标是迅速为美国、中国和世界各地的患者提供更好的治疗，彰显全球合作在推进癌症研究和治疗方面的影响。

如需了解更多信息，请访问纪念斯隆-凯特琳癌症中心网站。

Targeting KRAS in cancer

Anupriya Singhal,  Bob T. Li &  Eileen M. O’Reilly 

Nature Magazine, April 18, 2024

This piece in Nature Medicine that outlines the strategic thinking and future directions in the KRAS battle. Combination therapies against KRAS are underway, and first-in-human clinical trials of new allele specific molecules are already here, including promising inhibitors of KRAS G12D.

Apart from furthering our advances against lung cancers, we have a comprehensive plan to beat some of the most recalcitrant malignancies.

The full article is behind a paywall at Nature Magazine.

Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid Tumors

Oncology Live – June 13, 2023

C4C Taskforce Member Dr Bob T. Li discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.

Watch the interview on Oncology Live

Breakthrough Lung Cancer Treatment FOUND in Precision Medicine | Dr. Bob Li

Centerpoint, February 21, 2023

On Centerpoint, Dr. Bob Li joins Doug McKelway to discuss new breakthroughs in the area of precision medicine and its effectiveness against lung cancer.

Watch the full Interview on YouTube

Study on International Regulatory Harmonization Published in Harvard Business Review

Call for a Human Moonshot at Forbes China Healthcare Summit

Greg Simon, the Founding Executive Director of the White House Cancer Moonshot called for a “Human Moonshot” to promote international cancer clinical trials cooperation and bring breakthroughs to people all over the world

FDA grants double accelerated approval of trastuzmab deruxtecan (Enhertu)

FDA granted accelerated approval of trastuzumab deruxtecan (Enhertu) for patients with HER2-low breast cancer and HER2-mutant lung cancer based on international trials.

A Post-Pandemic Era White Paper Published in Nature Magazine

European Union Clinical Trials Regulation Came into Effect

Biden reignites the Cancer Moonshot, setting ambitious goals: to reduce the death rate from cancer by at least 50 percent over the next 25 years

International Cancer Coalition Launch

In 2021, the International Cancer Coalition officially launched at the Bloomberg New Economy Forum in Singapore.